These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 3588282)

  • 1. [Virus inactivation in plasma fractions for therapeutic use].
    Burnouf T; Martinache L; Goudemand M
    Nouv Rev Fr Hematol (1978); 1987; 29(1):93-6. PubMed ID: 3588282
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Photochemical inactivation of viruses and bacteriophage in plasma and plasma fractions.
    Morel P; Lin L; Wiesehahn G; Corash L
    Blood Cells; 1992; 18(1):27-41; Discussion 41-2. PubMed ID: 1617190
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inactivation of virus in intravenous immunoglobulin G using solvent/detergent treatment and pasteurization.
    Aghaie A; Pourfatollah AA; Bathaie SZ; Moazzeni SM; Khorsand Mohammad Pour H; Sharifi Z
    Hum Antibodies; 2008; 17(3-4):79-84. PubMed ID: 19029665
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preparation, purification and virus inactivation of intravenous immunoglobulin from human plasma.
    Aghaie A; Pourfatollah AA; Bathaie SZ; Moazzeni SM; Khorsand Mohammad Pour H; Banazadeh S
    Hum Antibodies; 2010; 19(1):1-6. PubMed ID: 20555125
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Partitioning and inactivation of viruses during isolation of albumin and immunoglobulins by cold ethanol fractionation.
    Morgenthaler JJ; Omar A
    Dev Biol Stand; 1993; 81():185-90. PubMed ID: 8174802
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Evaluation of viral safety of a high-purity human factor VIII concentrate submitted to 2 specific virus inactivation treatments (FANDHI)].
    Ristol P; Gensana M; Fernández J; Massot M; Biescas H; Darling A; Jorquera JI; Vericat F
    Sangre (Barc); 1996 Apr; 41(2):131-6. PubMed ID: 9045353
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inactivation of viruses in blood and plasma products.
    Suomela H
    Transfus Med Rev; 1993 Jan; 7(1):42-57. PubMed ID: 8431658
    [No Abstract]   [Full Text] [Related]  

  • 8. Viral safety of solvent-detergent treated blood products.
    Horowitz B; Prince AM; Horowitz MS; Watklevicz C
    Dev Biol Stand; 1993; 81():147-61. PubMed ID: 8174797
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inactivation of viruses and safety of stable plasma products.
    Morgenthaler JJ
    Beitr Infusionsther; 1989; 24():33-9. PubMed ID: 2481546
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Resistance of porcine circovirus and chicken anemia virus to virus inactivation procedures used for blood products.
    Welch J; Bienek C; Gomperts E; Simmonds P
    Transfusion; 2006 Nov; 46(11):1951-8. PubMed ID: 17076851
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dry-heat treatment process for enhancing viral safety of an antihemophilic factor VIII concentrate prepared from human plasma.
    Kim IS; Choi YW; Kang Y; Sung HM; Shin JS
    J Microbiol Biotechnol; 2008 May; 18(5):997-1003. PubMed ID: 18633304
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Purification of intravenous immunoglobulin G from human plasma--aspects of yield and virus safety.
    Buchacher A; Iberer G
    Biotechnol J; 2006 Feb; 1(2):148-63. PubMed ID: 16892245
    [TBL] [Abstract][Full Text] [Related]  

  • 13. At what stage should virus inactivation be carried out?
    Dorner F; Barrett PN; Eibl J
    Dev Biol Stand; 1993; 81():137-43. PubMed ID: 8174796
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New developments in plasma fractionation and virus inactivation.
    Morgenthaler JJ
    Vox Sang; 2000; 78 Suppl 2():217-21. PubMed ID: 10938956
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A solvent I detergent treated, pasteurised and highly purified factor VIII concentrate.
    Schwinn H; Stadler M; Josic D; Bal F; Gehringer W; Nur I; Schütz R
    Arzneimittelforschung; 1994 Feb; 44(2):188-91. PubMed ID: 8147954
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inactivation of pathogens in single units of therapeutic fresh plasma by irradiation with ultraviolet light.
    Mohr H; Gravemann U; Müller TH
    Transfusion; 2009 Oct; 49(10):2144-51. PubMed ID: 19497052
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Virus safety of pooled fresh-frozen plasma inactivated by solvent/detergent treatment.
    Prince AM; Horowitz B
    Beitr Infusionsther; 1993; 31():21-4. PubMed ID: 7693256
    [No Abstract]   [Full Text] [Related]  

  • 18. Laboratory and preclinical evaluation of the virus safety of coagulation factor concentrates.
    Horowitz B; Prince AM
    Dev Biol Stand; 1987; 67():291-302. PubMed ID: 3609483
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Viral safety considerations in immunoglobulin preparations].
    Gómez Manzano P; Escrivá CA; Salmerón García F; Alonso Verduras C
    Sangre (Barc); 1997 Jun; 42(3):199-203. PubMed ID: 9381262
    [No Abstract]   [Full Text] [Related]  

  • 20. Inactivation of hepatitis B and non-A, non-B viruses by combined use of Tween 80, beta-propiolactone, and ultraviolet irradiation.
    Prince AM; Stephan W; Kotitschke R; Brotman B
    Thromb Haemost; 1983 Aug; 50(2):534-6. PubMed ID: 6415846
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.